FMP
NASDAQ
8.25 USD
0.56 (6.79%)
Mr. Philip Astley-Sparke F.S.A.
Healthcare
Biotechnology
https://www.replimune.com
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise cause...
0001737953
US76029N1063
76029N106
500 Unicorn Park Drive
781 222 9600
US
284
Jul 20, 2018
0001737953
NASDAQ
Biotechnology
Healthcare
76029N106
US76029N1063
US
8.25
1.23
1.48M
506.45M
-
5.89-24.81
1.47
-
-
-
-
-2.61
-
https://www.replimune.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.